Anti-GLP-1 (Mid-molecule specific)

Cat.No. HYB 147-12B

Cat. No.
HYB 147-12B
Product name
Anti-GLP-1 (Mid-molecule specific)
Description

Mouse monoclonal antibody, biotinylated

Specificity

Reacts with all forms of GLP-1, including precursor and GLP-1(9-37) /GLP-1(9-36amide) metabolite HYB 147-12 cross-reacts with Liraglutide. 

Immunogen

Synthetic GLP-1(7-36)amide coupled to carrier

Application
Species reactivity (positive)
Human
Species reactivity (negative)
Not determined
Subclass

IgG1/k

Gene ID
2641
Clone number
4F3
Epitope

Mid-molecular epitope of GLP-1

Content

50 µL, 1 mg/mL +/- 15%. See Certificate of Analysis for details.

Purification
Biotinylated
Form
Liquid
Solvent
0.01 M phosphate buffer, pH 7.4, with 0.14 M NaCl and 15 mM sodium azide
Storage
4-8ºC without exposure to light. No precautions necessary during handling.
Target

Glucagon-like peptide-1(7-36)amide (GLP-1(7-36)amide) is the principal active form of GLP-1, the other being GLP-1(7-37). GLP-1 is a peptide hormone of the glucagon family, produced by the L cells of the intestinal mucosa from the same prohormone as glucagon. The active forms are potent stimulators of glucose-dependent insulin secretion. The sequence of GLP-1 is fully conserved in all mammalian species examined so far.

Application 1

ELISA

Biotinylated HYB 147-12 is the preferred detection antibody for measuring C-terminally amidated forms of GLP-1 in combination with HYB 147-06 as capture antibody (1). HYB 147-12 can be used as a capture antibody in combination with ABS 046-03B as a detection antibody for measuring non-amidated GLP-1 forms and cross- reacting about 16% with C-terminally amidated GLP-1. Results show detection limits of 44pmol/L which is 10-20 times higher than the basal concentration of GLP-1, so the assays have to be optimized. 
This uses HYB 147-06 as capture antibody in combination with biotinylated detection antibody HYB 147-12 to measure the sum of GLP-1(7-36)amide, GLP-1(1-36)amide and GLP-1(9-36)amide in biological samples. Relative to measuring the two active forms of GLP-1, the responses are reduced by not measuring the contribution of GLP-1(7- 37) to the overall response, but this is compensated for by measuring an approximately equal contribution from GLP-1(1-36)amide. However, the GLP-1(9-36)amide degradation product is also measured, augmenting the response above that of the active forms alone. This assay cannot detect changes in active GLP-1 in response to treatment with DPP-4 inhibitors, and is therefore only suitable for experiments in which changes in GLP-1 degradation are irrelevant.